Open Orphan #ORPH – Venn Life Sciences New Contract Win

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce Open Orphan’s Paris subsidiary Venn Life Sciences (“Venn”) has secured an important new contract to support a major European pharmaceutical company. The […]

Open Orphan #ORPH – hVIVO to present at 2020 ERS International Congress

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce that its subsidiary, hVIVO, will be presenting at the European Respiratory Society Congress being held on 7th – 9th September, 2020. The presentation will […]

Open Orphan #ORPH – Major New Contract Win with Top 3 Pharma Company

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new contract, valued at £4m, with a top 3 global pharmaceutical company to be the sponsor of and provide a respiratory syncytial […]

Open Orphan #ORPH – New Contract Win with Carna Bioscience

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce the signing of a new contract with Carna Bioscience ( www.carnabio.com ) for a First In Human Clinical pharmacology trial. The contract […]

Open Orphan #ORPH Awarded Contract From Codagenix Inc For COVID-19 Vaccine Trial

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new contract with Codagenix Inc. (“Codagenix”) to conduct a first in human (Phase I) trial evaluating safety and immunogenicity of a single-dose, […]